Fyzomol-M Forte

Fyzomol-M Forte is a fixed-dose combination oral tablet developed and marketed by Marriott Pharmaceuticals, primarily used for the management of dysmenorrhea and mild-to-moderate pain. It combines 500 mg of mefenamic acid, a non-steroidal anti-inflammatory drug (NSAID), with 325 mg of paracetamol (acetaminophen). Mefenamic acid acts by inhibiting the cyclooxygenase enzymes COX-1 and COX-2, which reduces the production of prostaglandins responsible for inflammation and pain. Paracetamol provides complementary analgesic and antipyretic effects through central mechanisms that are not fully defined but are thought to involve the modulation of central prostaglandin synthesis and the endocannabinoid system. This combination is positioned within Marriott's gynecological product portfolio for menstrual pain relief.

Brand names

Fyzomol-M Forte

Other names

mefenamic acid + paracetamolmefenamic acid + acetaminophen